ReviewJournal of clinical medicine2023
Stent Thrombosis and Restenosis with Contemporary Drug-Eluting Stents: Predictors and Current Evidence.
Review in Journal of clinical medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06822322 (The European Bifurcation Club Randomized Trial of Stepwise Provisional Stenting Versus Drug Coated Balloon Therapy for Non-left Main True Coronary Bifurcations - EBC DCB Study), which is not on this map. Cited by 40 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The European Bifurcation Club Randomized Trial of Stepwise Provisional Stenting Versus Drug Coated Balloon Therapy for Non-left Main True Coronary Bifurcations - EBC DCB Study
Who cites it
40 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Efficacy of clopidogrel monotherapy versus aspirin monotherapy after percutaneous coronary intervention.Journal of thrombosis and thrombolysis · 2026Pooled it
- Outcomes of first-generation versus second-generation drug-eluting stents in calcified coronary lesions: A meta-analysis.Narra J · 2025Pooled it
- Risk Factors and Incidence for In-Stent Restenosis with Drug-Eluting Stent: A Systematic Review and Meta-Analysis.Reviews in cardiovascular medicine · 2024Pooled it
- Site-Specific Antithrombotic Therapy: 24-Month Outcomes of the Randomized DESyne BDS Plus Trial Using a Novel Triple-Drug Eluting Coronary Implant With Two Anticoagulants and Sirolimus.Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2025Trial
- Cardiovascular stent technologies for coronary and valvular heart disease: the potential of 3D printing for stent fabrication.Nature reviews. Cardiology · 2026Review
- Stent Undersizing and Malapposition: Mechanical Causes of Acute and Late Stent Failure.Reviews in cardiovascular medicine · 2026Review
- Biodegradable polymer-based stents: materials, design, and biomedical applications.RSC advances · 2026Review
- Position Statement on the Management of Antithrombotic and Anticoagulant Therapy in Dengue - 2026.Arquivos brasileiros de cardiologia · 2026Article
- Effectiveness and Safety of Biodegradable Polymer-Coated Everolimus-Eluting Stent in Multivessel Coronary Artery Disease in Routine Clinical Practice: A Korean Multicenter, Prospective, and Observational Study.Journal of Korean medical science · 2026Observational
- Review
- Invest-to-treat drug-coated balloon strategy in chronic total occlusion percutaneous intervention for high-risk stent failure patients.Cardiology journal · 2026Article
- Conservative management without routine bailout stent for non-flow-limiting dissection after DCB angioplasty: a prospective three-arm study.Frontiers in cardiovascular medicine · 2026Article
- Association of systemic inflammatory index and HbA1c with in-stent restenosis in arteriosclerosis obliterans patients after stenting: a propensity score-matched analysis.American journal of translational research · 2026Article
- Summary of the best evidence for dyadic disease management in patients who have undergone coronary stenting and their family caregivers.Frontiers in cardiovascular medicine · 2026Review
- High-Intensity Exercise After Percutaneous Coronary Intervention in Previously Physically Active Patients: One-Year Clinical Outcomes.Scandinavian journal of medicine & science in sports · 2025Article
- Nitric oxide releasing graphene for next-generation therapeutics.Advanced drug delivery reviews · 2025Review
- In Vitro Evaluation of the Effect of Stenting on Hematological, Hemorheological and Hemodynamic Parameters, in Various Stent Configurations and Flow Conditions.Cardiovascular engineering and technology · 2025Article
- Unveiling the Causes of Acute and Non-Acute Myocardial Ischemic Syndromes: The Role of Optical Coherence Tomography.Medicina (Kaunas, Lithuania) · 2025Review
- Clinical safety and performance of a biodegradable polymer-coated sirolimus-eluting stent in an all-comers population: results from the S-FLEX Russia registry.AsiaIntervention · 2025Article
- Patient-specific coronary angioplasty simulations - A mixed-dimensional finite element modeling approach.Computers in biology and medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Iterations in stent technologies, advances in pharmacotherapy, and awareness of the implications of implantation techniques have markedly reduced the risk of stent failure, both in the form of stent thrombosis (ST) and in-stent restenosis (ISR). However, given the number of percutaneous coronary interventions (PCI) performed worldwide every year, ST and ISR, albeit occurring at a fairly low rate, represent a public health problem even with contemporary DES platforms. The understanding of mechanisms and risk factors for these two PCI complications has been of fundamental importance for the parallel evolution of stent technologies. Risk factors associated with ST and ISR are usually divided into patient-, lesion-, device- and procedure-related. A number of studies have shown how certain risk factors are related to early (1 month) versus late/very late ST (between 1 month and 1 year and >1 year, respectively). However, more research is required to conclusively show the role of time-dependence of risk factors also in the incidence of ISR (early [1 year] or late [>1 year]). A thorough risk assessment is required due to the complex etiology of ST and ISR. The most effective strategy to treat ST and ISR is still to prevent them; hence, it is crucial to identify patient-, lesion-, device- and procedure-related predictors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.